One year in review
One year in review 2019: Sjögren’s syndrome
G. Cafaro1, C. Croia2, O.D. Argyropoulou3, M.C. Leone4, M. Orlandi5, F. Finamore6, A. Cecchettini7, F. Ferro8, C. Baldini9, E. Bartoloni10
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Immuno-Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Italy.
- Laboratorio Proteomica, CNR Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.baldini74@gmail.com
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
CER12551
2019 Vol.37, N°3 ,Suppl.118
PI 0003, PF 0015
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 31464675 [PubMed]
Received: 01/07/2019
Accepted : 01/07/2019
In Press: 16/07/2019
Published: 27/08/2019
Abstract
Primary Sjögren’s syndrome (pSS) is a complex and heterogeneous disorder characterised by a wide spectrum of glandular and extra-glandular features. Novel insights into disease pathogenesis and the discovery of novel biomarkers are allowing us to characterise the disease not only phenotypically on the basis of clinical presentation, but also on the basis of the endotype. Ultimately, a better stratification of patients may pave new avenues for novel targeted therapies, opening new possibilities for the application of personalised medicine in pSS.
